Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Lung Cancer

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 20%High 3 · 60%

Progression‐free survival · People with advanced non‐small cell lung cancer

The review found no eligible studies for this question.

1 finding from 1 review

Therapeutic vaccines for advanced non‐small cell lung cancer 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Progression‐free survival · EGFR M+ patients with NSCLC

Erlotinib leads to lower progression‐free survival compared with control (high certainty).

1 finding from 1 review

Progression‐free survival · EGFR M+ patients with NSCLC

Gefitinib leads to lower progression‐free survival compared with paclitaxel + carboplatin (high certainty).

1 finding from 1 review

Progression‐free survival · EGFR M+ patients with NSCLC

Gefitinib probably leads to lower progression‐free survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).

1 finding from 1 review

Progression‐free survival · EGFR M+ patients with NSCLC

Afatinib leads to lower progression‐free survival compared with chemotherapy (high certainty).

1 finding from 1 review